International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

A Review Article: Effects of Oral Contraceptive Pills on Menstrual Cycle, Pregnancy, and Thyroid Gland

Akshay Sharma[1], Dheeraj Kumar Vishwakarma[2], Shivani Kumari[3], Deovrat Kumar[4]

[1,2,4]Haridwar University, Roorkee, Uttarakhand
[3]Shridhar University, Pilani, Rajasthan,

Abstract
Oral contraceptive pills (OCPs) are often used for both birth control and hormone modulation. They have a substantial impact on the menstrual cycle, pregnancy prevention, and general endocrine function, including the thyroid gland. This review examines how OCPs affect menstrual control, pregnancy prevention, and thyroid hormone levels. Understanding these interactions is critical for doctors managing patients on OCPs and women making informed reproductive health decisions.

Keywords: Oral Contraceptive Pills, Menstrual Cycle, Pregnancy and Thyroid Gland.

1. Introduction

Wide range of effective and safe oral contraceptive pills are available in the contemporary world. Oral contraceptive pills are one of the most commonly used methods of contraception, with millions of women relying on them for family planning and hormonal regulation. OCPs contain synthetic versions of estrogen and progesterone that mimic the body's natural hormones to prevent ovulation. Beyond pregnancy prevention, they are often used to manage menstrual disorders such as dysmenorrhea, menorrhagia, and irregular cycles.

However, the endocrine system is complex, and the hormonal impact of OCPs extends beyond reproductive organs. The thyroid gland, which plays a pivotal role in metabolism and hormone regulation, can also be affected by long-term OCP use. This review focuses on the implications of OCP use on the menstrual cycle, pregnancy prevention, and thyroid function, discussing the current literature and providing clinical insights into these interactions.

2. Review of Literature

A. Effect of OCPs on the Menstrual Cycle

OCPs are known to regulate the menstrual cycle by suppressing ovulation and stabilizing hormone levels. They also reduce the severity of menstrual pain and bleeding, making them a popular choice for managing conditions like endometriosis and polycystic ovarian syndrome (PCOS). Studies show that women on OCPs experience more regular and lighter periods, with fewer occurrences of ovulation-related symptoms such as mittelschmerz (mid-cycle pain) and premenstrual syndrome (PMS).

B. Pregnancy Prevention

The primary mechanism by which OCPs prevent pregnancy is the inhibition of ovulation through the suppression of the hypothalamic-pituitary-gonadal (HPG) axis. By maintaining steady levels of synthetic estrogen and progesterone, OCPs prevent the natural hormonal surge that triggers ovulation. Additional mechanisms include thickening of cervical mucus, which acts as a barrier to sperm, and altering the endometrial lining, making it less conducive for implantation. Numerous clinical trials confirm the high efficacy of OCPs in preventing pregnancy, with a typical use failure rate of around 7% and a perfect use failure rate of less than 1%.

C. Thyroid Function and OCPs

OCPs influence thyroid function indirectly through their effects on estrogen levels. Estrogen increases the production of thyroid-binding globulin (TBG), a protein that binds thyroid hormones, reducing the availability of free, active thyroid hormones. Despite this change, studies suggest that most women with normal thyroid function remain euthyroid (normal thyroid function) while on OCPs. However, in women with pre-existing thyroid disorders, OCP use may require adjustments in thyroid hormone therapy, as free thyroxine (FT4) levels can fluctuate due to changes in TBG levels. Clinical monitoring of thyroid function in women on long-term OCPs is therefore recommended, particularly in those with known thyroid dysfunction.

3. Results and Discussion

The effects of OCPs on menstrual regulation, pregnancy prevention, and thyroid function are summarized below:

Parameter	Effect of OCPs	Clinical Implications
Menstrual Cycle	egulates periods, reduces menstrual pain, and bleeding	Beneficial for women with dysmenorrhea, PCOS, endometriosis
Pregnancy Prevention	Inhibits ovulation, thickens cervical mucus	High efficacy with both perfect and typical use; secondary effects on implantation
Thyroid Function	Increases thyroid-binding globulin (TBG)	Potential need for monitoring in women with thyroid disorders; adjustment of therapy may be required

Menstrual Cycle Regulation: Women taking OCPs benefit from lighter, more predictable cycles, reducing the burden of menstrual disorders. This is a valuable option for women seeking both contraceptive and therapeutic benefits from OCPs.

Pregnancy Prevention: OCPs are highly effective at preventing pregnancy through multiple mechanisms. They are also widely available and easily reversible, making them a preferred option for many women.

Thyroid Function: Though most women with normal thyroid function remain unaffected, those with pre-existing thyroid conditions may need closer monitoring. Adjustments in thyroid medication may be necessary to account for altered TBG levels.

4. Conclusion

Oral contraceptive pills offer multiple benefits beyond contraception, particularly in menstrual cycle regu-

lation. However, their use also impacts thyroid function, especially in women with underlying thyroid disorders. Clinicians should be aware of these interactions and manage OCP use accordingly, particularly in patients requiring thyroid hormone therapy. Further research is needed to fully elucidate the long-term effects of OCPs on thyroid function, particularly in vulnerable populations.

Reference:

1. Jacobstein R. Long acting and permanent contraception: an international development, service delivery perspective. J Midwifery Womens Health. 2007;52(4):361–7.
2. Family Health International. Addressing Unmet Need for Family Planning in Africa. 2007. [Accessed 15 Sept 2017]; Available from: http://www.k4health.
1. org/ system/files/ unmetneed for FP_Africa. pdf
2. Kulier R, O'Brien PA, Helmerhorst FM, Usher-Patel M, D'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev. 2007;4:CD005347.
3. Fotherby K, Yong-En S, Howard G, Elder MG, Muggeridge J. Return of ovulation and fertility in women using norethisteroneoenanthate.
4. Contraception. 1984;29:447–54.
5. Pardhaisong T, Gray RH, McDaniel EB. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in northern Thailand. Lancet. 1980;l:509–12.
6. Kaplan B, Nahum R, Yairi Y, Hirsch M, Pardo J, Yogev Y, et al. Use of various contraceptive methods and time of conception in a communitybased population. Eur J Obstet Gynecol Reprod Biol. 2005;123:72–6.
7. McIver B, Romanski SA, Nippoldt TB. Evaluation and management of amenorrhea. Mayo Clin Proc. 1997;72:1161–9.
8. Shearman RP. Amenorrhea after treatment with oral contraceptives. Lancet. 1966;2:1110–1.
9. Horowitz BJ, Solomkin M, Edelstein SW. The oversuppression syndrome. Obstet Gynecol. 1968;31:387–9.
10. Halbert DR, Christian CD. Amenorrhea following oral contraceptives. Obste Gynecol. ;34:161–7.
11. MacLeod SC, Parker AS, Perlin IA. The oversuppression syndrome. Am J Gynecol. 1970;106:359–64.
12. Bracken MB, Hellenbrand KG, Holford TR. Conception delay after contraceptive use: the effect of estrogen dose. Fertil Steril. 1990;53:21–7.
13. Harlap S, Baras M. Conception-waits in fertile women after stopping oral contraceptives. Int J Fertil. 1984;29:73–80.
14. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74:439–45.
15. Hassan MA, Killick SR. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity? Hum Reprod. 2004;19:
16. 344–51.
17. Davis AR, Kroll R, Soltes B, Zhang N, Grubb GS, Constantine GD. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Steril. 2008;89:1059–63.
18. Archer DF, Thomas RL. The fallacy of the postpill amenorrhea syndrome. Clin Obstet Gynecol. 1981;24:943–50.

19. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility.7th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2004.
20. Tolis G, Ruggere D, Popkin DR, Chow J, Boyd ME, De Leon A, et al. Prolonged amenorrhea and oral contraceptives. Fertil Steril. 1979;32:265–8.
21. Vessey MP, Wright NH, McPherson K, Wiggins P. Fertility after stopping different methods of contraception. BMJ. 1978;1:265–7.
22. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long term use of levonorgestrelreleasing intrauterine . Int J Gynecol Pathol. 1986;5:235–41.
23. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISM statement. PLoS Med. 2009;6:e1000097.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
25. Affandi B. Pregnancy after removal of etonogestrel implant contraceptive (Implanon). Med J Indones. 1999;8:62–4.
26. Buckshee K, Chatterjee P, Dhall GI, et al. Return of fertility following discontinuation of Norplant(R)-II subdermal implants. ICMR task force on hormonal contraception. Contraception. 1995;51:237–42.
27. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after of Norplant capsules, Norplant II rods, or levonorgestrel releasing of copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166:1208–13.
28. Singh K, Viegas OA, Singh P, Ratnam SS. Norplant contraceptive subdermal implants: two-year experience in Singapore. Adv Contracept. 1989;5:13–21.
29. Affandi B, Santoso SS, Djajadilaga, Hadisaputra W, Moeloek FA, Prihartono J, et al. Pregnancy after removal of Norplant implants contraceptive. Contraception. 1987;36:203–9.
30. Diaz S, Pavez M, Cardenas H, Croxatto HB. Recovery of fertility and outcome of planned pregnancies after the removal of Norplant subdermal implants or copper-T IUDs. Contraception. 1987;35:569–79.
31. Bahamondes L, Lavin P, Ojeda G, et al. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclo-fem. Contraception. 1997;55:307–10.
32. Anonymous. ICMR (Indian Council of Medical Research) task force on hormonal contraception. Return of fertility following discontinuation of an contraceptive-norethisterone enanthate (NETEN) 200mg dose. Contraception. 1986;34:573–82.
33. Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril. 2009;91:659–63.
34. Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol. 2009;114:616–22.
35. Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H. Fertility after discontinuation of treatment with an oral contraceptive containing 30 mcg of ethinyl estradiol and 2 mg of dienogest. Fertil Steril. 2006;85:1812–9.
36. Farrow A, Hull MGR, Northstone K, Taylor H, Ford WCL, Golding J. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod. 2002;10:2754–61.
37. Zimmermann T, Dietrich H, Wisser KH, Munch C. Fertility after discontinuation of the dienogest-containing oral contraceptive Valette. First

38. Delbarge W, Batar I, Bafort M, et al. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system. Eur J Contracept Reprod Health Care. 2002;7:24–30.
39. Tadesse E. Return of fertility after an IUD removal for planned pregnancy: a six-year prospective study. East Afr Med J. 1996;73:169–71.
40. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception.1992;46:575–84.